Drug strategy blocks leading driver of cancer
Using a new strategy, UC San Francisco researchers have succeeded in making small molecules that irreversibly target a mutant form of this protein, called ras, without binding to the normal form. This feature distinguishes the molecules from all other targeted drug treatments in cancer, according to the researchers. When tested on human lung cancer cells grown in culture, the molecules efficiently killed the ras-driven cancer cells. …